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Stress and stress hormones, glucocorticoids (GCs), exert widespread actions in central nervous system, ranging from the regulation
of gene transcription, cellular signaling, modulation of synaptic structure, and transmission and glial function to behavior. Their
actions are mediated by glucocorticoid and mineralocorticoid receptors which are nuclear receptors/transcription factors. While
GCs primarily act to maintain homeostasis by inducing physiological and behavioral adaptation, prolonged exposure to stress and
elevated GC levels may result in neuro- and psychopathology. There is now ample evidence for cause-effect relationships between
prolonged stress, elevated GC levels, and cognitive and mood disorders while the evidence for a link between chronic stress/GC
and neurodegenerative disorders such as Alzheimer’s (AD) and Parkinson’s (PD) diseases is growing. This brief review considers
some of the cellular mechanisms through which stress and GC may contribute to the pathogenesis of AD and PD.
1. Introduction
Stress is broadly defined as an actual or anticipated threat
of well-being or disruption of organism homeostasis [1].
Although the sensing and reaction to stress evolved to pro-
mote adaptation, modern workstyles and lifestyles represent
challenges that render individuals susceptible to physical
and mental disorders [2–5]. Multiple factors influence an
individual’s ability to cope with stress, for example, early life
experiences, gender, or personality traits. Both vulnerability
and resilience may be determined by genetic and epigenetic
(gene environmental interactions) background [5–9].
Since the discovery of the communication between
hypothalamus and pituitary in early 70s that opens a new
window in our understanding of the brain-body commu-
nication, there are plethora of studies describing the high
biological significance of stress and its responses which
enables various adaptive processes to changing conditions.
The most easily measureable and critical physiological res-
ponse to stress involves the release of glucocorticoids (glu-
cocorticoids, GCs). These hormones are synthesized and
secreted into systemic circulation from the adrenal glands
following stimulation by the anterior pituitary hormone
adrenocorticotropic hormone (ACTH) [1]. The release of
ACTH itself is increased in response to the secretion of
corticotropin-releasing hormone (CRH) and arginine vaso-
pressin (AVP) from neurons in the hypothalamic paraven-
tricular nucleus (PVN). Together, the hypothalamus, pitu-
itary, and adrenal glands constitute the so-called hypo-
thalamo-pituitary-adrenal (HPA) axis, which plays an essen-
tial role in the adaptive response to psychogenic (e.g., fear)
and physical (e.g., cellular lesion or pathogen invasion)
stressors. The adaptive responses that are initiated by GCs
occur in multiple tissues and involve alterations in numerous
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physiological (e.g., metabolic, cardiovascular, and immune)
as well as behavioral (e.g., emotion, cognition, and motor)
processes [1, 10–12]. Normally, GC-driven negative feedback
mechanisms at the different levels of the HPA axis serve to
normalize GC secretion and restore homeostasis; however,
and depending on the type, duration, and intensity of
the stressful stimulus, GC hypersecretion may persist and
become a potential threat for health [1].
There is now abundant evidence that GCs can exert pro-
foundmodulatory effects on a variety of brain functions from
early development through to late life [12]. Their actions are
mediated by two receptors: the mineralocorticoid receptor
(MR) and glucocorticoid receptor (GR), which belong to
the superfamily of nuclear receptors that act as transcrip-
tion modulators [13, 14]. In the brain, GR is ubiquitously
expressed, whereas MR expression is more restricted to just
a few structures (hippocampus, locus coeruleus, amygdala,
prefrontal cortex, and nucleus of the solitary tract, as well
as PVN neurons). MR is also present in nonneuronal cells,
namely, in glia and epithelial cells of the choroid plexus and
ependyma [15].
Binding assays using 3[H] corticosterone have shown
the MR has a 10-fold higher affinity (𝐾
𝑑
= 0.5 nM) for GC
compared to GR (𝐾
𝑑
= 5 nM), which means that, at basal
GC levels, MR is occupied and activated [16] whereas GR
is only activated when GC levels reach a certain level, for
example, during the circadian peak of GC secretion and
during stress [17]. Importantly, brain MR and GR both
respond to the same endogenous ligand (cortisol in humans
and larger mammals, corticosterone in rodents); further, MR
and GR were reported to colocalize in the same pyramidal
and granular neurons of the hippocampus [17]. Given the
GR and MR colocalization and relatively small difference
in their affinity for endogenous GCs, the question arises as
to whether they regulate distinct genes and/or coregulate
transcription by heterodimerization. Heterodimerization of
GR andMRwas shownwith high concentration of GC (stress
level) in the nuclei of cultured hippocampal neurons. More-
over, evidence suggests that their cellular responses through
regulation of distinct gene expression (as homodimers)
depend strongly upon specific recruitment of coregulators
[18, 19].
Synthetic GCs (e.g., dexamethasone, methylpredniso-
lone) are routinely used in clinical situations due to their pow-
erful anti-inflammatory and immunosuppressive actions.
However, a growing body of evidence suggests that high
GC exposure in early life can adversely program the HPA
axis and increase the susceptibility to develop metabolic,
neuropsychiatric, and neurodegenerative disorders [5, 20,
21]. In addition, there is now ample experimental evidence
where elevated GC levels and prolonged exposure to stressful
conditions induce structural remodeling of neurons with
synaptic loss as well as alterations in glial functions, which
are frequently maladaptive [22]; see also Figure 1. In this brief
review we discuss some of current knowledge about cellular
targets andmechanisms through which stress and altered GC
levels trigger changes in the brain that may lead towards the
development and progression of neurodegenerative patholo-
gies such as Alzheimer’s (AD) and Parkinson (PD) disease.
2. From Stress-Driven Brain Programming to
Neurodegenerative Pathologies
In addition to nongenomic mechanisms that are still incom-
pletely identified [23], chronic stress and GC levels most
likely influence neuronal function and connectivity by acti-
vating GR-mediated transcription. GRs are normally located
in the cytoplasm in association with chaperone proteins
such as the heat shock proteins Hsp90 and 70 and the
immunophilins FKBP51 and FKBP52. Upon GC binding,
conformational change of the GR-chaperone complex results
in nuclear translocation of the GR [24, 25]. In the nucleus,
GR binds to specific regions of DNA, which possess glu-
cocorticoid response elements (GRE) within the promoters
of target genes, leading to cell-type and context-dependent
gene expression [26–28]. Transcriptional regulation by GR
may occur by (a) direct binding of GR homodimers to
GRE within DNA sequences to stimulate transcription, for
example,mitogen-activated protein kinase phosphatase-1 gene;
(b) direct binding to negative GRE elements to repress
transcription; the gene encoding the prohormone fromwhich
ACTH is derived (proopiomelanocortin, POMC), CRH, and
the CRH receptor genes are examples of negatively regulated
genes; and (c) trans-repression or “tethering,” that is, associ-
ation with other transcriptional factors that inhibit the tran-
scriptional activity of GR. In the brain, identification of GR-
modulated genes is difficult due to the anatomical complexity
and cellular heterogeneity. Nevertheless, transcriptomic stud-
ies in the hippocampus have identified functional classes of
GR target genes which include genes coding for neurotrans-
mitter catabolism, neurotrophic factors and their receptors,
signal transduction, energy metabolism, and cell adhesion
[29].
In addition to altering gene expression, growing evi-
dence suggests that epigenetic mechanisms represent a
means through which stress and GCs can leave long-
lasting “memories” of past experiences which, in turn,
contributes to shaping the organism’s physical and mental
health trajectory [21, 30, 31]; see Figure 1. Broadly, epi-
genetics refers to stable changes in the regulation and/or
function of DNA, RNA, and/or proteins that do not involve
alterations of their primary sequences. Two well-known
examples of epigenetic marks induced by environmental
stimuli (e.g., stress) are DNA methylation and histone mod-
ification. The first evidence of epigenetic programing in
the brain by early life adversity showed that poor maternal
care in rats leads to methylation of exon 1
7
in the GR
promoter, being accompanied by aberrant behaviors and
altered HPA axis responses during adulthood [32, 33]. Sub-
sequently, similar mechanisms were reported in humans
who had experienced childhood adversity [34] and in
infants born to depressed mothers [35]. The earlier studies
in rats were replicated in mice in paradigms of prenatal
GC exposure and early postnatal stress; we showed that
these pre- and postnatal manipulations resulted in epige-
netic modifications of the promoters of neurotransmitter
(dopamine receptor 2) [36], GR, and various GR target
genes [37, 38] with long-lasting maladaptive behavioral
consequences.
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Figure 1: Cellular targets and actions of chronic stress mediated by glucocorticoid receptors. This schema depicts some cellular targets and
mechanisms that are targeted by glucocorticoids (GCs), whose actions are mediated by glucocorticoid receptors (GR). GCs are secreted
under conditions of stress; neuronal damage and brain pathologies are a common consequence of persistently elevated GC secretion. GC can
trigger mitochondrial dysfunction and the apoptotic machinery, as well as cell cycle arrest and cell death. In addition, stress/GC may induce
neuronal atrophy and synaptic dysfunction/loss by stimulating hyperphosphorylation of the cytoskeletal protein Tau, thus disturbing the
integrity of the cytoskeleton and missorting Tau at synapses. Together, these latter events may eventually result in the degradation of synaptic
proteins and receptors and consequently, synaptic plasticity. Stress and GC are also established as modulators of microglial activation and
neuroinflammatory processes. Lastly, accumulating evidence indicates that stress and GC can influence neuronal structure and function
through epigenetic mechanisms.
Recent studies also suggest that early life events (e.g.,
intrauterine infections, maternal stress, and poor maternal
and perinatal nutrition) may play a role in the onset of
Alzheimer’s disease (AD), an age-related neurodegenerative
disorder characterized progressive memory and cognitive
deficits [39]. From this perspective, AD is probably not
determined by a single etiologic factor but results from
the interplay between genetic and environmental factors
throughout life, possibly explaining why monozygous twins
can be discordant for AD. Albeit this is still controversial
and the literature is sparse, it has been suggested that adverse
events in early life, for example, maternal stress and poor
maternal and perinatal nutrition, can potentially predispose
eventually to AD through epigenetic programing of spe-
cific genes/pathways related to AD neurodegeneration. For
example, maternal separation for the first 3 weeks of rodent
life is shown to result in increase of AD cellular pathways
(e.g., APP misprocessing and Tau hyperphosphorylation; see
below) followed by synaptic and neuronal damage as well as
cognitive deficits in adulthood [40] suggesting the potential
impact of early-life stress exposure to the precipitation of AD
neurodegeneration later in life. While most current research
on epigenetic mechanisms focuses on DNAmethylation, one
recent study demonstrated that GC, acting via GR, increase
the levels of histone deacetylase 2 (HDAC2), an enzyme
regulating DNA expression, in the CK-p25 mouse [41]. In
general, how early life stressors reprogram the fetal brain
and contribute to late-life development of neurodegenerative
disorders (e.g., AD) is emerging as an exciting, new research
field [42].
Experimental evidence in animal studies indicates that
stressful events in early life can impact the etiopathogenesis
of another neurodegenerative disorder, Parkinson’s disease
(PD), which is characterized by both motor and nonmotor
symptoms. Depression, anxiety, apathy and interestingly
fatigue are common nonmotor features occurring in around
30 to 58% of patients before the onset of motor symptoms
in PD patients. In addition, the prevalence of cognitive
impairment in PD ranges from 19 to 36% [43]. The cellular
mechanisms underlying these nonmotor symptoms in PD
may share similarities to AD, particularly with respect to the
molecular pathways activated by stress.
Maternal separation was reported to exacerbate motor
deficits and nigrostriatal lesion in an experimental model
of PD [44]. In an interesting study, pups of female animals,
exposed to the bacterial endotoxin lipopolysaccharide (LPS)
during pregnancy, showed loss of dopaminergic (DA) neu-
rons. Since loss of dopaminergic neurons as well as related
motor deficits is a characteristic feature of PD pathology,
the above findings suggest that high LPS levels in mothers
might interfere with the development of DA neurons in the
fetus, thus enhancing susceptibility to PD [45]. Accordingly,
developmental stress may represent the first imprint in the
brain and accumulatively with later stressful stimuli to affect
nigrostriatal neurochemical reserve and precipitate the PD
phenotype [46].
3. Chronic Stress and GC as a Risk
Factor for AD
AD is a multifactorial neurodegenerative disorder with
complex etiopathology. Besides early life stress (see above),
accumulating clinical evidence strongly suggests that chronic
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stress in adulthood as well as elevated GC levels may have a
role in the development of AD pathology and related demen-
tia [47, 48]. In fact, high levels of cortisol are commonly
found in AD patients’ plasma, saliva, and/or CSF [49–53];
AD patients also show higher total daily secretion of cortisol
[54].The potential link between stress/GC and AD described
above is strengthened by emerging evidence that stress may
advance the age of onset of the familial formofAD [47, 48, 55]
and that cortisol levels in AD patients correlate with their
memory deficits [56, 57] suggesting a role for GC on AD.
Nevertheless, in the absence of longitudinal studies it is not
clear from the available evidence as to whether elevated GC
secretion is a cause or a consequence of AD disease.
An important brain area in unraveling the interrelation-
ship between stress, elevated GC, and AD pathology is the
hippocampus, which is among the first areas affected in AD
patients. Hippocampal lesions in AD brain are not only asso-
ciated with the deficits in declarative, spatial, and contextual
memory but could also be responsible for the suggested
HPA axis dysregulation and the subsequent overproduction
of GC found in AD patients due to the inhibitory role that
hippocampus exhibits on HPA axis. Indeed, previous studies
from our laboratories (and others) have shown that hip-
pocampal neurons are particularly vulnerable to the adverse
effects of stress and GC, their effects being manifested as
dendritic atrophy and apoptotic cell death [22, 58]. Moreover,
a large number of studies have shown that stress and elevated
GC levels affect neurogenesis in adult brain with subsequent
impairments of mood and cognitive behavior [59, 60]. More
specifically, both acute and chronic exposure stress reduces
adult neurogenesis, affecting hippocampal cell proliferation
and, in certain studies, survival of newborns [61, 62]. In
addition, administration of corticosterone showed the ability
of glucocorticoids to damage neurogenesis in adult brain by
inhibiting cell proliferation, differentiation and survival [63]
while the deleterious effect of stress and/or corticosterone
on neurogenesis is GC-dependent [64]. In a vicious cycle,
alteration in neurogenesis of adult brain is recently shown to
impact on GC negative feedback on the central elements reg-
ulating HPA axis activity [65, 66]. Moreover, perturbations
in adult neurogenesis may also be related to the cognitive
deficits associated with AD whereas contradictory findings
support both increases and decreases of neurogenesis in
brain of AD patients and Tg animal models [67]. Here, it
is also worthwhile noting that stress and GC interfere with
hippocampal-prefrontal cortex (PFC) connectivity [68] and
dendritic and synaptic plasticity in the PFC, thus disrupting
executive functions [58]. These PFC structural deficits are
also likely to have consequences for central regulation of the
HPA axis providing another neuroanatomical link between
HPA axis dysregulation and subsequent GC hypersecretion
and AD pathology.
4. Impact of Stress and GC on
Neurodegenerative Mechanisms of AD
At the molecular level, AD pathology is characterized by
amyloid beta (A𝛽) that forms deposits (senile plaques)
and hyperphosphorylated forms of the cytoskeletal protein
Tau that aggregate into neurofibrillary tangles (NFT) [69–
71]. A𝛽 is the proteolytic product of a large transmembrane
protein called amyloid precursor protein (APP), which is
sequentially cleaved by 𝛽-secretase (BACE-1) and 𝛾-secretase
(a complex of enzymes) to generate the production of A𝛽;
this cellular pathway is often called APP misprocessing.
Many studies have demonstrated that the products of APP
misprocessing trigger neuropathological processes associated
withAD such as synapticmalfunction (including impairment
of long-term potentiation), neuronal atrophy and synaptic
disintegration and loss [72] as well as mitochondrial dysfunc-
tion, oxidative stress, and glial activation [73].
Although still a subject of debate, several studies sug-
gest that A𝛽 also triggers the abnormal hyperphosphoryla-
tion of Tau, NFT formation, and neuronal loss. Moreover,
cumulative evidence suggests that the detrimental effects
of A𝛽 are abolished in Tau-KO mice, highlighting the
essential mediatory role of Tau protein in the neuro- and
synaptotoxic effects of A𝛽 [73–77]. Further support for an
essential role of Tau in the establishment of AD pathology
derives from clinical findings that have consistently shown
that the cognitive deficits in AD patients correlate better
with NFT rather with A𝛽 deposition per se. Moreover,
Go´mez-Isla et al. [78] demonstrated a strong correlation
between neuronal loss in the cerebral cortex and increased
NFT burden with disease progression; no such correla-
tion was found with A𝛽. In addition, the reduction of
hippocampal volume in AD patients correlates better with
CSF levels of phosphorylated Tau than with those of A𝛽
[79].
The evidence of a causal relationship between stress/GC
and AD includes that from studies showing that either high
GC levels and/or stress increase the production of A𝛽 and
exacerbate memory deficits in transgenic mouse models of
AD [80, 81]. Specifically, chronic immobilization stress in
transgenic mice expressing the amyloid precursor protein
(APP) V717ICT-100 (a mutation which results in aggressive
early onset AD) accelerates the appearance of extracellular
A𝛽 deposits and worsens memory deficits. Similar findings
were obtained in vivo when young (prodromal) 3XTg-AD
mice were treated with the synthetic GC, dexamethasone
[80]; the same authors also reported dexamethasone-induced
APPmisprocessing in the N2A cell line, a findingmatched by
our own observations in PC12 cells [82]. Further, Green et al.
demonstrated that GCs upregulate the transcription of APP
and 𝛽-secretase, whose promoters contain a glucocorticoid
response element (GRE) [80]. Consistent with the above, our
studies inmiddle aged rats showed that stress and chronicGC
drive APP processing towards the generation of A𝛽 and its
precursormolecule (C99), both ofwhich have neurotoxic and
cognition-impairing properties [83] (see also Figure 1). The
latter changes were accompanied by increases in the levels of
𝛽-secretase (BACE-1) and Nicastrin, a protein found in the
𝛾-secretase complex. Further experiments that attempted to
mimic intermittent stressful events thatmay exert cumulative
effects over the lifetime indicated that GC potentiate the APP
misprocessing pathway in previously stressed rats receiving
A𝛽-infusions [83] (see Figure 2).
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Figure 2: Proposed model through which chronic stress and glucocorticoids (GCs) may contribute to Alzheimer disease (AD) pathology.
Themodel illustrates how chronic stress and high GC levels can trigger AD pathology; the figure is based on experimental evidence obtained
in cellular and animal models of AD. Extended exposure to stress/high GC levels activates the amyloidogenic pathway of amyloid precursor
protein (APP).This so-calledmisprocessing of APP involves the sequential cleavage of APP by 𝛽- and 𝛾-secretases, resulting in the generation
of toxic amyloid 𝛽 (A𝛽). Subsequently, the cytoskeletal protein Tau, which is mainly localized in axons (red in the representation of a
healthy neuron), becomes aberrantly hyperphosphorylated, catalyzed by glycogen synthase kinase (GSK3𝛽) and/or cyclin-dependent kinase
5 (CDK5). Hyperphosphorylated Tau is trafficked to, and accumulates in, the somatodendritic compartment, where it oligomerizes and forms
insoluble aggregates (red in the diseased neuron). In addition, the abnormal conformation adopted by Tau and caspase 3-mediated truncation
of Tau is accompanied by dysregulation of the molecular chaperones Hsp90 and Hsp70, which normally serve to promote Tau degradation
(left panel). This cascade of events causes neuronal atrophy and loss, followed by cognitive impairments.
In addition to triggering the amyloidogenic pathway,
high levels of GC and stress can also instigate the aberrant
hyperphosphorylation of Tau protein that also characterized
AD brain. Among the first reports suggesting a potential con-
nection between GCs and Tau was that from Stein-Behrens
et al. [84] who demonstrated that GC exacerbate kainic acid-
induced hippocampal neuronal loss with a contemporaneous
increase in Tau immunoreactivity. A later study showed that
chronic treatment of 3xTg AD mice with dexamethasone
leads to the somatodendritic accumulation of Tau in the
hippocampus, amygdala and cortex [80].
Supporting those earlier studies, we showed that chronic
stress or GC increase the levels of aberrantly hyperphos-
phorylated Tau in the rat hippocampus and PFC [85] (see
Figure 2). Importantly, the hyperphosphorylation occurred
at certain Tau epitopes that are strongly implicated in
cytoskeletal dysfunction and synaptic loss (e.g., pSer262)
[86, 87] and hippocampal atrophy (e.g., pThr231) [88] in AD
patients. Here, it is pertinent to note that the extent of phos-
phorylation at Thr231- and Ser262-Tau correlates strongly
with severity of memory impairment, speed of mental pro-
cessing, and executive functioning in AD patients [89–91].
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Although chronic stress and GC treatment exert similar, but
not identical, effects on individual Tau phosphoepitopes in
vivo and in vitro [82], the overall evidence points to GC as the
key mediator of the AD-like pathology induced by stress. On
the other hand, some studies have suggested a role for at least
one other stress-related molecule, namely, corticotrophin-
releasing hormone (CRH), as deletion of the CRH receptor
1 gene in mice was found to block the detrimental effects of
stress on Tau phosphorylation [92, 93].
As shown at Figure 2, information on the mechanisms
underlying stress/GC-induced hyperphosphorylation of Tau
is only just beginning to emerge. For example, in vitro exper-
iments indicate that the effects of stress/GC are mediated
by glycogen synthase kinase 3 (GSK3) and cyclin-dependent
kinase 5 (CDK5), both of which have well-established roles
in Tau hyperphosphorylation and the subsequent disruption
of microtubules, features seen in the AD brain [82]. We now
also know that GC exposure increases Tau accumulation by
affecting turnover of the protein by reducing its degradation
[82]; the latter appears to result from dysregulation of molec-
ular chaperones (e.g., Hsp90 and Hsp70) that are responsible
for Tau proteostasis [94] (see Figure 2). Interestingly, both
these heat shock proteins also serve to maintain GR in a
high affinity state, suggesting that these proteins may be the
point at which GC/GR signaling intersects with the cellular
machinery that regulates Tau degradation. Using a transgenic
mouse that expresses human P301L-Tau (the most common
Taumutation), we recently showed that chronic stress triggers
different aspects of Tau pathology in addition to inducing, its
aberrant hyperphosphorylation and aggregation of Tau into
insoluble forms [94]. Adding to the mechanistic understand-
ing of stress-driven aggregation of Tau, we also showed that
chronic stress enhances caspase 3-mediated truncation of Tau
at its C-terminal, leading to an abnormal conformation of Tau
in the hippocampus (Figure 2). This truncation-dependent
misfolding of Tau into an abnormal conformation is known to
facilitate nucleation and recruitment of other Tau molecules
into neurotoxic aggregates [95, 96] before NFT are formed
[95, 97, 98].
It is interesting to note that chronically elevated GC
secretion, usually in response to stress, is a major cause
of major depressive illness [99]. In light of the increasing
volume of data implicating high GC levels in AD, it is
important to consider that epidemiological studies implicate
depression as a risk factor for the development of AD; this
is supported by the observation that previously depressed
subjects have increased amyloid plaque and NFT loads [100].
Different studies have in fact sought to discriminate between
subjects undergoing normal aging from those suffering from
depression or AD through the measurement of the vari-
ous APP cleavage products [101–104]. While much remains
to be discovered about the potentially important role of
depression in AD pathology, it is interesting to note that
antidepressant drugs, whose actions often involve reductions
in GC secretion, inhibit the proteolytic cleavage of APP into
amyloidogenic products [104, 105].
Lastly, it deserves mentioning that a recent epidemi-
ological study found that the prevalence and incidence
of dementia in war veterans suffering from posttraumatic
depression (PTSD) is twice as high as that in age-matched
PTSD-free subjects [106]. While PTSD is a condition quite
distinct from major depression, these findings hint at the
important influence lifetime stressful experiences can have
on mental health, possibly through epigenetic mechanisms.
The findings are also interesting since PTSD patients usually
show hypoactivity of the HPA axis (versus hyperactivity
in depression), suggesting that just a single—but major
stressful—event involving transient GC hypersecretion can
have long-lasting neuropathological consequences.
4.1. Inflammation and AD: Role of GCs? Chronic inflam-
mation is one of the central pathological features of AD
with reactive microglia and astrocytes surrounding senile
𝛽-amyloid plaques observed in both postmortem AD brain
and animal models [107, 108]. Evidence from human studies
suggests that glial activation is an early event; thus inflamma-
tory markers are present in mild cognitive impairment cases
that eventually progress to AD [109]. Thus proinflammatory
cytokines produced by activated glia in response to amyloid
fibrils would be expected to activate HPA axis and increase
GC levels. In vitro studies clearly show that A𝛽 can be
taken up through phagocytosis in microglia and thereafter
degraded [110, 111]; thus, in AD setting, microglial likely have
a beneficial role early in pathology. However, elevation of
proinflammatory cytokines such as IL-1𝛽may also participate
in mood disorders such as depression [112] in AD.
The importance of immune-related responses in the
emergence of A𝛽 burden, tau pathology, and dementia is
gaining momentum as molecular comprehension of their
actions is increasingly unraveled by human genetic and
animal studies. Recent genome-wide association studies
have identified variants in at least 16 genes involved in
microglia/macrophage functions as risks for developing AD
[113]. Among them, 𝜀4 allele of APOE gene is a known strong
risk factor, accelerating the age of onset of AD. APOE is pro-
duced by both microglia and astrocytes; it regulates not only
lipid and A𝛽metabolism but also microglial chemotaxis and
proinflammatory cytokine expression [114]. Recently, another
strong link was found between variants in TREM2 gene and
AD. TREM2 is specifically expressed inmyeloid cells where it
promotes phagocytosis whilst inhibiting cytokine production
[115]. These and most other GWAS genes identified [113] are
involved in aberrant microglial/macrophage responses with
regard to A𝛽 clearance and spread of Tau pathology.
In addition to genetic susceptibility, prolonged exposure
of A𝛽 affects microglial functions. Thus, crucial microglial
functions such as motility and phagocytosis were impaired
in APP/PS1 mice [116]; also in these mice the levels of
A𝛽 receptors (SRA, CD36, RAGE) and A𝛽 degrading
enzymes (neprilysin, MMP9) were decreased with concomi-
tant increase in proinflammatory cytokines TNF-𝛼 and IL-
1𝛽 [117]. Age, a primary risk factor for AD, is also an
important contributor to dysfunction of innate immune
responses. Microglial dystrophy and fragmentation observed
in aging brain [118] occur before the appearance of abnormal
Tau suggesting dysfunctional microglia could contribute to
appearance of Tau pathology.
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Chronic stress through GCs is known to prime and
augment neuroinflammatory processes in the cortex and
hippocampus upon subsequent proinflammatory challenges
such as LPS [119, 120]. Peripheral infections and stress are
both known to affect the activation state of microglia and
in AD pathology both could have detrimental effects on
the functions of microglia. There is little known on how
glucocorticoids influence glial functions during prodromal
to emergence and progression of AD pathology. It would be
important to understand whether GC through GR has any
role in A𝛽 degradation in astrocytes or myeloid cells.
5. Role of Glucocorticoids in Onset and
Progression of Parkinson’s Disease
Parkinson’s disease (PD) is a complex systemic and progres-
sive neurodegenerative disease associated with both motor
and nonmotor symptoms. The cardinal motor symptoms
such as akinesia, resting tremor and rigiditymostly arise from
preferential and substantial loss of dopaminergic neurons
(50–60%) in the substantia nigra pars compacta (SNpc)
with significant dopamine depletion in the sensorimotor
striatum. The nonmotor symptoms include olfactory dys-
function and sleep behavior disorder as well asmood changes
and cognitive impairment as discussed above. One principle
histopathological feature is the presence of Lewy bodies
(LBs), which are proteinaceous inclusions containing mainly
structurally altered presynaptic protein, alpha-synuclein,
which, as recent evidence shows, plays a central role in PD
pathology. Alpha-synuclein LB deposition was used by Braak
et al. [121] as a principle pathological marker to monitor
the progression and severity of PD. PD is believed to origi-
nate from olfactory nucleus and autonomic nervous system
progressing in an ascending manner to many brain regions
such as substantia nigra, striatum, raphe, locus coeruleus,
hypothalamic nuclei, hippocampus, amygdala, and cerebral
cortex accounting for both motor and nonmotor symptoms
[121–123]. Thus, for example, PD patients with cortical LBs
also suffer from dementia and visual hallucinations [124].
While several gene mutations have been identified in
familial forms of PD, the majority of PD cases are sporadic
and of unknown etiology. Nevertheless, significant advances
in the last decade on PD genetics, particularly genome-
wide association, as well as pathophysiological mechanisms
in various PD model systems, have contributed much to
our comprehension of PD. Cellular processes such as oxida-
tive and nitrative stress, mitochondrial dysfunction, and
deregulated intracellular calcium levels as well as damaged
proteostasis related to alpha-synuclein aggregation are the
most studied and relate to dopamine neurodegeneration
[125].
As in AD patients, the HPA axis is likely dysregulated
in PD patients. Specifically, previous studies [54, 126–128]
including our ownwork [129] show that plasma cortisol levels
are significantly higher in idiopathic PD patients compared
to control subjects; however, these high levels do not corre-
late to disease duration or to L-3,4-dihydroxyphenylalanine
(L-DOPA) treatment. Interestingly, the diurnal pattern of
cortisol secretion in PD patients, in particular the normally
quiescent nocturnal cortisol secretory pattern, is affected
[54].
6. The Neurodegenerative Potential of
Altered GC Levels in PD Pathology
Chronically elevated GC levels in PD patients suggest that
HPA regulated-stress responses may impact PD pathology.
Indeed, the role of stress was proposed as one of the
underlying causes of PD as clinical reports show that stress
triggers the appearance of PD symptoms or exacerbates
the motor symptoms [130–132]. The role of stress in PD is
supported by few experimental studies such as food depriva-
tion and tail-shock and maternal separation aggravate motor
deficits in the 6-hydroxydopamine (6-OHDA) PD model (6-
hydroxydopamine local injections lesions the nigrostriatal
pathway) [133]. In combined chronic stress exposure with
6-OHDA lesion, stress was shown to worsen the 6-OHDA-
driven motor deficits, aggravate the neurodegeneration of
nigrostriatal system, and completely block compensatory
recovery of motor tasks [131, 134]. The precise actions of
high GC levels in motor control following nigrostriatal
lesions are yet not known. Analysis of GR expression in PD
brains revealed that GR levels were reduced in the SNpc
and augmented in the putamen, compared to age-matched
control subjects; similar results were found in MPTP- (1-
methyl 4-phenyl 1,2,3,6-tetrahydropyridine-) treated mice
[129]. GCs are known to profoundly modulate dopamin-
ergic neurotransmission. The role of GC on the limbic
arm of the dopaminergic circuitry related to reward and
motivation as well as neuropsychiatric diseases has been
extensively investigated (see below). Thus, from its known
roles in mesolimbic circuitry, it has been postulated that
GR also likely affect motor automated or habitual skills of
the sensorimotor circuitry in the striatum by influencing
NMDA/AMPA receptor functions in D1 and D2 receptor-
medium spiny neurons (Figure 3). Indeed, it has been shown
that chronic stress leads to opposing structural changes in
the limbic/associative and sensorimotor striatal circuitrywith
atrophy in the former and hypertrophy of sensorimotor
striatum, leading to habit behavior [135]. In addition, the
roles of both glucocorticoids and noradrenalinewere recently
reported in habit memory [136]. It is possible that GR-
mediated changes in the putamen during the prodromal stage
of PD play a role in preventing the appearance of motor
symptoms, culminating in dopamine depletion and death of
dopaminergic neurons in the substantia nigra.
Altered stress responses most likely play an important
role in nonmotor PD symptoms, particularly anxiety, depres-
sion, and mild cognitive impairment, which often precede
motor symptoms. Interestingly, there is also evidence in
PD for lower novelty-seeking and high harm avoidance
personality traits with anxiety-associated symptoms [43, 137].
These observations suggest that, in the initial disease stage,
stress-related alterations in GC-GR activity could impact
both the motivation/cognitive-associated dopaminergic as
well as nondopaminergic (serotonergic and noradrenergic)
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Stress (GR)?
High glucocorticoid levels
Prodromal Clinical motor symptoms
Stress-GR: depression 
Dopamine nigrostriatal system 
Dopamine mesolimbic system
Dopamine
VTA
SN
Modulation MSN D1R-glutamatergic transmission
Modulation MSN D1R, D2R-
glutamatergic transmission
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glutamatergic transmission
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alpha synuclein
Activated microglia
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↓ dopamine
↓↓ dopamine
↑ habit behavior
↓ motivation, social interaction
↓ GR-neuronal death—glial activationGR—neuronal survival
Figure 3: Putative impact of elevated GC levels on GR function in nigrostriatal and mesolimbic dopaminergic systems in PD. Stress-
level elevation of GCs may be an early feature of PD, potentially impacting both motor and nonmotor dopaminergic systems. Mesolimbic
dopaminergic circuitry is likely affected through structural and functional changes occurring in D1RMSNs.These changes lead to depression
and reduced motivation and social interaction which are key prodromal features of PD. Dopaminergic neurons in VTA are relatively spared
in PD. In the nigrostriatal system, high levels of GCs initially protect dopaminergic neurons of substantia nigra through dampening the
immune responses, namely, mediated by activated microglia and astrocytes. In the putamen, high stress levels of GCs through GR augment
habit learning and may act to prevent the appearance of motor symptoms. With disease progression, GR function is affected, leading to
chronic glial and immune activation, which exacerbates dopamine neurodegeneration with significant dopamine depletion in the striatum.
Changes in GR activity may also affect striatal D1 and D2R MSNs further participating in the appearance of clinical motor symptoms.
neuronal circuitry. This would also implicate dopaminergic
neurons in the ventral tegmentum area (VTA), which
although relatively spared in PD are well-known to regulate
reward and aversion by stress and have been implicated
not only in addiction but also depression involving the
transcriptional factor CREB and BDNF [138–141]. On the
other hand, dorsolateral dopamine neurons in the SN (vul-
nerable in PD) were shown to respond to tasks involving
working memory [142]; thus, their demise could explain, in
part, the cognitive deficits observed in PD. Studies on the
dopaminergic transmission during stress have revealed the
complexity of the system. In fact, firing patterns of dopamine
neurons in VTA correlated with depressive-like behaviors in
mice, although the effect appears to depend on the stress
paradigm used to induce the depressive-like behavior [139,
143]. Electrophysiological evidence implicates changes in
both D1R and D2R-medium spiny neurons (MSNs) in the
ventral striatum [144], but the depressive-behaviors seems to
preferentially affect D1R MSNs [145] (Figure 3). Glutamater-
gic receptors, NMDA and AMPA receptor functions were
shown to be also altered in the D1RMSNs, notably NMDAR-
dependent LTD, reduced AMPA/NMDA receptor ratio and
increased endocytosis of AMPA receptors [146].
7. Role of Glucocorticoid Receptors in
Inflammation-Induced Neurodegenerative
Processes and Nonmotor Symptoms in
Parkinson’s Disease
Accumulating evidence points to inflammation resulting
from chronic activation of innate and adaptive immune
cells as playing an important role in both neurodegener-
ative processes and in nonmotor symptoms of PD. Using
radiolabeled ligand 11C-PK-11195 for translocator protein,
Positron Emission Tomography (PET) studies in PD patients
revealed an early activation of microglia in many brain
regions including basal ganglia and midbrain [147, 148].
Furthermore, postmortem studies as well as analyses of
serum and cerebrospinal fluid from PD showed high levels
of proinflammatory mediators such as TNF-𝛼, IL-1𝛽, iNOS,
IFN-𝛾, and COX-2 [149]. In line with observations in PD
patients, presence of inflammatory mediators and glial reac-
tivity in striatum and substantia nigra is a key feature inmany
of the experimental animal models of PD [150]. Evidence
from recent genome-wide studies points to involvement
of the immune system in the etiology of idiopathic PD.
A number of susceptibility loci identified relate to genes
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expressed in immune cells such as HLA-DQB1, LRRK2 or
BST-1 [151, 152]. In addition, identified PD risk factors [such
as age, environmental toxins (e.g., heavymetals or pesticides,)
traumatic brain injury, and bacterial or viral infections]
activate immune responses in periphery and brain.
7.1. GR Regulation of Inflammation Important for Dopamine
Neuronal Survival. Activated microglia functioning as in-
nate-immune competent cells are likely involved in releas-
ing the above inflammatory molecules, thereby inducing
dopamine neurodegeneration. Indeed, the important role of
these proinflammatorymediators in promoting degeneration
of dopaminergic neurons of substantia nigra was demon-
strated using mice with specific knockout of these genes
[153–156]. Many of the proinflammatory mediators found in
PD patients are transcriptional targets of GR. The synthetic
analogue of GCs, dexamethasone, was shown to attenuate
dopamine neuronal loss by precluding activated microglia
from releasing toxic inflammatory molecules [157, 158]. In
adrenalectomized mice (lacking endogenous production of
GCs), dopamine neuronal loss was augmented following
MPTP intoxication indicating that endogenous GCs do play
a role in protecting dopamine neurons [159]. Examination of
GR in microglia revealed an increase in nuclear localization
of GR following MPTP treatment in mice, which coincided
with a rise in systemic corticosterone levels, indicating that
GR is activated in microglia during the degeneration of
dopamine neurons [129]. The unequivocal evidence that
GR in microglia normally protects dopamine neurons was
provided by experiments withmice inwhich theGR genewas
selectively deleted in microglia/macrophages. MPTP treat-
ment in these mice resulted in increased dopamine neuronal
loss as well as increased microglial activation and expression
of proinflammatory mediators [129]. Indeed, the absence of
GR in microglia resulted in sustained activation of NF-𝜅B
as was shown in these microglial GR mutants. The above
findings have a significant relevance for PD pathogenesis as
nuclear expression of p65 subunit of NF-𝜅B, indicative of
transcriptional activity, was found in the substantia nigra
microglia of PD postmortem [160].
Inflammatory reaction mediated by immune-competent
cells such as microglia is normally a very tightly regu-
lated process of limited duration. It is very likely that
the processes involved in the regulation of glial immune
responses including the expression and secretion of inflam-
matory mediators are compromised in PD and also AD
resulting in a chronic inflammatory state with sustained
activation of glia spanning many years. One likely factor
contributing to dysfunction of glial immune responses is
aging. Immune-regulatory processes are compromised in
aging (immunosenescence) and also during chronic stress
[161] where there is an increased susceptibility to infections
as well as proinflammatory cytokine production [162]. In
aging, microglia show enhanced sensitivity to inflammatory
stimuli, a process called “priming” which could be also
induced by chronic stress and a dysregulated HPA axis. In
this regard, there are several studies showing that chronically
elevated GCs levels in response to different stressors cause
proinflammatory cytokine production and sensitization or
“priming” of microglia. Importantly, subsequent inflamma-
tory or toxic stimuli result in aggravation of neuronal injury
[119, 120, 163]. Moreover high and sustained GCs can exac-
erbate inflammation because of GC resistance whereby GR
activity is affected.Thus it is plausible that GR transcriptional
activity regulating inflammatory response of microglia is
compromised inADandPDpatients who display persistently
high GC levels.
7.2. GR, Inflammation and Nonmotor PD Symptoms. Recent
experimental evidence shows that glia and peripheral
immune cells are activated upon chronic psychogenic stress
and that their actions are important in mood and behav-
ior [164–167]. Glial production of potent proinflammatory
cytokines such as TNF-𝛼, IL-6, and INF-𝛾 are implicated in
depression through stimulation of the kynurenine pathway
(shift of serotonin synthesis from tryptophan to kyneurin)
in activated astroglia, microglia, and infiltrating peripheral
immune cells. Kynurenine, produced from tryptophan by
activation of indoleamine 2,3-dioxygenase (IDO), can be
further converted to kynurenic acid or quinolinic acid,
the latter affecting the function of both monoaminergic
and glutamatergic neurons. Quinolinic acid toxicity with
increased glutamate release results in lipid peroxidation and
nitrative stress [168, 169] Evidence shows that the kynurenic
acid/tryptophan ratio is altered in CSF and serum in PD
patients [170].
Another means by which glial activation and proinflam-
matory cytokines promote mood anomalies in PD is through
reducing neurogenesis in hippocampal subgranular zone,
thus affecting hippocampus-mediated regulation of mood
and cognition [171].
8. Conclusion
Clinical and preclinical studies suggest that chronic stress/
elevated GC levels may be an etiological factor in the devel-
opment and progression of both AD and PD pathologies.
Growing evidence indicates that the pathological mani-
festations of chronic stress include neuronal and synaptic
atrophy/malfunction as well as immunosuppression, but our
understanding of the underpinning mechanisms is still poor
and calls for more research not only to identify therapeutic
inroads but, also, preventative measures or ways to delay
onset of disease.
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